Terminated × OTHER × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Clear all FLUBUTBI
Phase 3 Terminated
53 enrolled 11 charts
Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)
Phase 2 Terminated
51 enrolled 8 charts
Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia
Phase 2 Terminated
25 enrolled 8 charts
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
Phase 2 Terminated
31 enrolled 18 charts
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Phase 2 Terminated
150 enrolled
Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors
Phase 1 Terminated
8 enrolled
Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia
Phase 1/2 Terminated
9 enrolled 11 charts
Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors
Phase 2 Terminated
9 enrolled 11 charts
Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib
Phase 2 Terminated
14 enrolled
Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers
Phase 2 Terminated
1 enrolled 11 charts
Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia
Phase 1 Terminated
19 enrolled
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
Phase 1 Terminated
2 enrolled
PONS
Phase 2 Terminated
18 enrolled
DC Vaccination in CML
Phase 1/2 Terminated
1 enrolled
Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia
Phase 2 Terminated
12 enrolled 8 charts
Pharmacists Coordinated Care Oncology Model (PCOM) for Patients Taking Oral Anti-cancer Medications
Phase NA Terminated
6 enrolled
T-cell Depleted Alternative Donor Transplantation
Phase 2 Terminated
53 enrolled 14 charts
IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT
Phase 1 Terminated
6 enrolled
AFR22
Phase 2 Terminated
19 enrolled 4 charts
Stem Cell Transplant for Hematological Malignancy
Phase NA Terminated
330 enrolled 25 charts
Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies
Phase 2 Terminated
3 enrolled 17 charts
Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell Transplant
Phase 1 Terminated
13 enrolled
Cord Blood
Phase 1/2 Terminated
3 enrolled 8 charts
Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases
Phase NA Terminated
2 enrolled 11 charts
DECLINE
Phase 3 Terminated
14 enrolled
Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia
Phase 2 Terminated
4 enrolled 13 charts
Post Transplant Donor Lymphocyte Infusion
Phase 2 Terminated
57 enrolled 13 charts
Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT
Phase 2 Terminated
32 enrolled
Bortezomib in Treating Patients With Chronic Myelogenous Leukemia
Phase 2 Terminated
7 enrolled
Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia
Phase 2 Terminated
7 enrolled 5 charts
PEG-Intron For Chronic Myelogenous Leukemia Patients Unresponsive To Or Intolerant Of Roferon Or Intron
Phase 2 Terminated
1 enrolled
Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS)
Phase 2/3 Terminated
3 enrolled
Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C
Phase 2 Terminated
117 enrolled 6 charts
Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT
Phase 1 Terminated
1 enrolled
Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)
Phase 2 Terminated
5 enrolled 3 charts
Pilot Study to Assess Telemonitoring of Gleevec (Imatinib Mesylate) or Tasigna (Niltinib) Therapy
Phase NA Terminated
27 enrolled
Telemonitoring Study - for Chronic Myeloid Leukemia (CML)
Phase NA Terminated
14 enrolled
Chronic Myelod Leukemia Registry at Asan Medical Center
Terminated
100 enrolled
Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers
Phase 2 Terminated
15 enrolled 8 charts
Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells
Phase 1/2 Terminated
10 enrolled 13 charts
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
Phase 2 Terminated
5 enrolled 10 charts
Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies
Phase 2 Terminated
9 enrolled 13 charts
POE07-01
Phase 1 Terminated
35 enrolled
Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
Phase 2 Terminated
12 enrolled 12 charts
AHN-12 Biodistribution in Advanced Leukemia
Phase 1 Terminated
8 enrolled
Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases
Phase 1 Terminated
3 enrolled
Chemotherapy, Filgrastim and Peripheral Stem Cell Transplantation in Patients With Chronic Myelogenous Leukemia
Phase 2 Terminated
Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease
Phase 2 Terminated
13 enrolled 24 charts
Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation
Phase 2 Terminated
12 enrolled 12 charts
Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation
Phase 2 Terminated
14 enrolled 7 charts